-transparent.png){kind=logo}
Inhibition of protein synthesis can alter cellular responsiveness to the classical anticancer drugs. The in vitro response of Chinese hamster ovary (CHO) cells to cisplatin with or without sparsomycin (Sm) was studied with the use of [3H]leucine and [methyl-3H]thymidine incorporation and clonogenic assay. Pretreatment of exponentially growing CHO cells with 1 microgram Sm/ml for 3 or 5 hours decreased [3H]leucine incorporation by 20% and resulted in significant resistance to cisplatin (P = .005). Sm in a concentration of 10 micrograms/ml reduced [3H]leucine and [methyl-3H]thymidine incorporation after 3 hours by 92 and 84%, respectively, and resulted in potentiation of the cisplatin cytotoxicity (P = .004). This effect was the same in the case of nonproliferating cells (P = .005), while protection due to Sm (1 microgram/ml) was seen only during cell proliferation. Simultaneous incubation and postincubation with Sm proved to have much less or no potentiating effect on cisplatin. The mechanisms of both protection and potentiation are still not clear, but our data indicate that Sm is a promising drug for further studies on the modulation of the cancer cell response to classical anticancer drugs.
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
December 1966,
Biochimica et biophysica acta,
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
August 1994,
British journal of cancer,
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
May 1993,
Biochemical pharmacology,
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
January 2001,
Anticancer research,
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
April 1991,
Biochemical Society transactions,
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
February 1967,
Biochemistry,
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
June 1992,
Biochemistry,
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
January 1990,
Journal of cancer research and clinical oncology,
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
February 1974,
Biochemical pharmacology,
Z Zylicz, and
D J Wagener, and
H van Rennes, and
J M Wessels, and
E van der Kleijn, and
W J de Grip, and
L A van den Broek, and
H C Ottenheijm
December 1968,
Archives internationales de physiologie et de biochimie,
